Department of Radiology and Oncology - Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil; School of Medicine, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.
Department of Radiotherapy, Instituto do Câncer do Estado de São Paulo (ICESP) - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Hospital Vila Nova Star, São Paulo, Brazil.
J Sex Med. 2021 Aug;18(8):1461-1466. doi: 10.1016/j.jsxm.2021.05.015. Epub 2021 Jul 10.
Anal cancer is a rare disease, more prevalent in women. Men who have sex with men (MSM) are a high-risk neglected population.
The primary objective was to assess quality of life (QoL) and sexual function (SxF) among MSM treated with radical chemoradiation for anal cancer. Secondary objectives were to assess survivals and to describe the sexual habits of the target population.
Prospective single institution trial of MSM who were treated for anal cancer with curative intent between 2015 and 2019. QoL and SxF were the primary end-points and were assessed by validated questionnaires and sexual inventory. Overall survival, locoregional relapse-free, distant metastases free, and colostomy-free survivals were evaluated.
Quality of life and sexual function.
Nineteen patients were accrued between November 2015 and August 2019. Median age was 59.3 years. Stage III disease was 53.4% and mean tumor size was 5.4 cm. Fifteen (79.0%) patients were living with HIV (PLHIV). Median follow-up was 21.8 months. Mean overall survival, locoregional relapse-free survival, distant metastases-free survival, and colostomy-free survival were, respectively, 20.8, 17.2, 19.8 and 17.4 months. No median value was reached. QoL followed a trend among questionnaires with significantly worsened values by the end of treatment and a raise to maximum value by three months after treatment, followed by a stabilization reached at 12 months after treatment. IIEF questionnaire showed moderate erectile dysfunction among the population. Intercourse frequency followed QoL measures.
In a MSM population with anal canal cancer, QoL and SxF followed the same pattern up to one year after treatment. Most patients had their SxF compromised during follow-up as shown by IIEF levels and sexual inventory.
It is a single institution prospective trial with a limited sample size. Nevertheless, there are no studies addressing this minority population, quality of life or otherwise, making it unique and a special contribution for the literature.
Anal cancer and its treatment represent a burden to MSM regarding QoL and SxF. Mauro GP, da Conceição Vasconcelos KGM, Carvalho HDA, Quality of Life and Sexual Function of Men Who Have Sex With Men Treated for Anal Cancer: A Prospective Trial of a Neglected Population. J Sex Med 2021;18:1461-1466.
肛门癌是一种罕见疾病，在女性中更为常见。男男性行为者（MSM）是一个被忽视的高危人群。
主要目的是评估接受根治性放化疗的 MSM 肛门癌患者的生活质量（QoL）和性功能（SxF）。次要目标是评估生存率并描述目标人群的性习惯。
对 2015 年至 2019 年期间接受根治性放化疗的 MSM 肛门癌患者进行前瞻性单机构试验。QoL 和 SxF 是主要终点，并通过验证问卷和性库存进行评估。评估了总生存率、无局部区域复发、无远处转移和无结肠造口术的生存率。
2015 年 11 月至 2019 年 8 月期间共纳入 19 例患者。中位年龄为 59.3 岁。III 期疾病占 53.4%，平均肿瘤大小为 5.4cm。15 例（79.0%）患者患有 HIV（PLHIV）。中位随访时间为 21.8 个月。平均总生存率、无局部区域复发生存率、无远处转移生存率和无结肠造口术生存率分别为 20.8、17.2、19.8 和 17.4 个月。无中位值。QoL 遵循问卷中的趋势，治疗结束时值明显恶化，并在治疗后三个月达到最大值，随后在治疗后 12 个月稳定。IIEF 问卷显示人群中存在中度勃起功能障碍。性交频率与 QoL 测量结果一致。
在患有肛门腺癌的 MSM 人群中，QoL 和 SxF 在治疗后一年的时间内遵循相同的模式。正如 IIEF 水平和性库存所示，大多数患者在随访期间的 SxF 受到影响。
这是一项单机构前瞻性试验，样本量有限。然而，目前尚无针对这一少数人群的研究，包括生活质量或其他方面的研究，这使其成为文献中的独特贡献。
肛门癌及其治疗给 MSM 的生活质量和性功能带来了负担。
